Boundless Bio, Inc. (BOLD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Boundless Bio, Inc. on October 15, 2024, covering events occurring on October 11, 2024. The Company is a clinical-stage biopharmaceutical firm incorporated in Delaware and listed on the Nasdaq Global Select Market under the symbol BOLD.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure of CFO: Jami Rubin, Chief Financial Officer and Treasurer, terminated her employment effective October 11, 2024.
- Severance Arrangement: Ms. Rubin is eligible for severance benefits under the Company's Severance and Change in Control Severance Plan for a "Tier 2 Covered Employee" terminated other than for Cause, subject to a waiver and release of claims.
- Appointment of Interim CFO: David Hinkle, Senior Vice President, Finance & Controller, was appointed to serve as the Company's Treasurer, principal financial officer, and principal accounting officer effective October 11, 2024.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or discussion of operational risks beyond the standard disclosure of the executive transition. Mr. Hinkle brings significant experience from previous roles at Crinetics Pharmaceuticals, Ignyta, Receptos, Somaxon, and Digirad. An indemnification agreement was executed with Mr. Hinkle effective on the date of his appointment.
Key Facts for Investor Verification
- Confirm the specific financial terms of the severance package for Jami Rubin as detailed in the referenced Severance Plan (Exhibit 10.6 to the Q1 2024 10-Q).
- Verify the timeline for the search for a permanent Chief Financial Officer, as Mr. Hinkle's appointment is currently in an interim capacity.
- Review the Company's most recent 10-Q or 10-K for the latest financial position, as this 8-K does not update financial statements.